Dr. Norman Putzki, MD - SVP, Novartis - Gene Therapy And A New Era Of Neuroscience episode artwork

EPISODE · Dec 8, 2025 · 35 MIN

Dr. Norman Putzki, MD - SVP, Novartis - Gene Therapy And A New Era Of Neuroscience

from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. Norman Putzki

Send us Fan MailDr. Norman Putzki, MD is Senior Vice President, Global Clinical Development Head, and U.S. Development Site Head at Novartis ( https://www.novartis.com/ ) where he oversees global teams working on next-generation gene therapies, RNA-based medicines, targeted biologics, and innovative small molecules.Dr. Putzki most recently served as Global Head of Development for Neuroscience and Gene Therapy at Novartis, where he oversaw one of the world’s most ambitious pipelines aimed at transforming the lives of patients with neurological, neuromuscular, and rare genetic diseases.  A physician–scientist by training, with an MD from University of Duisburg Essen, Dr. Putzki has built a career at the intersection of clinical medicine, translational research, and large-scale drug development. Before joining Novartis, Dr. Putzki led programs across multiple therapeutic areas at Biogen Idec and has played key roles in advancing clinical treatments for conditions long considered intractable including MS and Parkison's disease.Beyond his scientific and clinical contributions, Dr. Putzki is widely recognized for his commitment to patient-centered innovation and his ability to bring together cutting-edge science, regulatory acumen, and real-world medical insight. Important Episode Links - Zolgensma Web Site - https://www.zolgensma.com/Itvisma Web Site - https://www.itvisma.com/Nature Medicine Papers For Itvisma Phase III study - Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial - https://www.nature.com/articles/s41591-025-04103-wIntrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial - https://www.nature.com/articles/s41591-025-04119-2#NormanPutzki #Novartis #Neuroscience #GeneTherapy #SpinalMuscularAtrophy #SMN1 #SurvivalMotorNeuron1 #Zolgensma #OnasemnogeneAbeparvovec #AdenoAssociatedVirusSerotype9 #AAV9 #SMA #AveXis #Itvisma #NewbornScreening #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Episode metadata supplied by the publisher feed · Published Dec 8, 2025

Embed this episode

Send us Fan Mail Dr. Norman Putzki, MD is Senior Vice President, Global Clinical Development Head, and U.S. Development Site Head at Novartis ( https://www.novartis.com/ ) where he oversees global teams working on next-generation gene therapies, RNA-based medicines, targeted biologics, and innovative small molecules. Dr. Putzki most recently served as Global Head of Development for Neuroscience and Gene Therapy at Novartis, where he oversaw one of the world’s most ambitious pipelines aimed a...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Dr. Norman Putzki, MD - SVP, Novartis - Gene Therapy And A New Era Of Neuroscience

0:00 35:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Progress, Potential, and Possibilities Podcast / Show?

This episode is 35 minutes long.

When was this Progress, Potential, and Possibilities Podcast / Show episode published?

This episode was published on December 8, 2025.

Can I download this Progress, Potential, and Possibilities Podcast / Show episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!